Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.

Anhui Provincial Hospital

5 clinical trials · 5 recruiting · OTHER_GOV

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Trials by Anhui Provincial Hospital

RECRUITINGEarly Phase 1NCT06462508

Head-to-head Comparison of [18F]F-PSMA-N5 With [68Ga]Ga-PSMA-11 PET/CT in PCa Diagnosis, Recurrence, and Metastasis

To prospectively evaluate the radiodrug biodistribution of a novel PET imaging agent \[18F\]F-PSMA-N5 in different organs of prostate cancer patients and its diagnostic efficacy...

Sponsor: Anhui Provincial HospitalEnrolling: 301 location
Prostate CancerPET/CT
RECRUITINGPhase 2NCT05407519

A Study to Evaluate Tislelizumab Combined With Sitravatinib as Adjuvant Therapy in Participants With HCC at High Risk...

This is an open label, multi-center, single arm study to evaluate the efficacy and safety of tislelizumab combined with sitravatinib as adjuvant therapy in hepatocellular...

Sponsor: Anhui Provincial HospitalEnrolling: 401 location
Hepatocellular Carcinoma
RECRUITINGPhase 1 / Phase 2NCT05937438

Postoperative Radiotherapy Followed by Immunotherapy for Locally Advanced Esophageal Carcinoma

Esophageal squamous cell carcinoma is a common malignancy in China. Although neoadjuvant chemoradiotherapy followed by esophagectomy remains a standard modality for locally...

Sponsor: Anhui Provincial HospitalEnrolling: 701 location
Esophageal Carcinoma
RECRUITINGNCT06602843

Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy

The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally...

Sponsor: Anhui Provincial HospitalEnrolling: 701 location
Esophageal Squamous Cell Carcinoma
RECRUITINGNCT07121777

Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases

This is an open label, single-site, dose-escalation study in up to 18 participants with treatment of Refractory Autoimmune Diseases. This study aims to evaluate the safety and...

Sponsor: Anhui Provincial HospitalEnrolling: 181 location
Autoimmune Diseases